导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.66% | 2597/4773 |
| 近一周 | -1.89% | 3083/5465 |
| 近一月 | -3.57% | 2639/5421 |
| 近一季 | -6.63% | 2482/5231 |
| 近半年 | -1.76% | 1891/4920 |
| 近一年 | 2.28% | 2310/4394 |
| 近两年 | 49.93% | 1502/2954 |
| 近三年 | 30.96% | 1055/2253 |
| 成立以来 | 148.59% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.68% 3345/4961 |
12.93% 2094/5312 |
- - |
- - |
| 2025 | 20.83% 2080/4813 |
-1.03% 2545/3635 |
2.34% 1635/4076 |
18.98% 2210/4524 |
0.27% 2091/4813 |
| 2024 | 17.77% 656/3463 |
2.97% 650/2808 |
-1.08% 918/3014 |
17.77% 1122/3129 |
-1.83% 1850/3463 |
| 2023 | -9.11% 1110/2656 |
4.66% 892/2280 |
-3.98% 991/2385 |
-2.87% 773/2515 |
-6.90% 1967/2655 |
| 2022 | -19.97% 920/2207 |
-14.51% 958/1919 |
7.20% 511/2016 |
-14.31% 1067/2113 |
1.90% 1094/2208 |
| 2021 | -2.54% 859/1822 |
-2.92% 726/1255 |
4.72% 852/1330 |
-5.56% 826/1466 |
1.52% 896/1822 |
| 2020 | 34.92% 431/1250 |
-9.42% 674/1028 |
14.36% 557/1067 |
14.25% 287/1164 |
14.00% 310/1184 |
| 2019 | 40.35% 255/1092 |
28.55% 301/754 |
-0.22% 237/804 |
1.76% 361/850 |
7.53% 426/918 |
| 2018 | -23.92% 308/834 |
- - |
- - |
- - |
-12.53% 455/691 |
| 2017 | 25.00% 117/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.57% 249/605 |
- - |
- - |
- - |
- - |
| 2015 | 5.93% 209/575 |
- - |
- - |
- - |
- - |
| 2014 | 54.37% 58/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 南方沪深300ETF VS. 长安沪深300非周期A(740101) |